D.A. Davidson & CO. cut its holdings in Adaptimmune Therapeutics PLC (NASDAQ:ADAP) by 3.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 36,011 shares of the biotechnology company’s stock after selling 1,326 shares during the quarter. D.A. Davidson & CO.’s holdings in Adaptimmune Therapeutics PLC were worth $161,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in ADAP. Point72 Asset Management L.P. purchased a new stake in shares of Adaptimmune Therapeutics PLC in the 1st quarter worth about $2,883,000. Baillie Gifford & Co. grew its position in shares of Adaptimmune Therapeutics PLC by 43.7% in the 2nd quarter. Baillie Gifford & Co. now owns 1,323,308 shares of the biotechnology company’s stock worth $5,941,000 after buying an additional 402,324 shares during the period. Renaissance Technologies LLC grew its position in shares of Adaptimmune Therapeutics PLC by 75.4% in the 1st quarter. Renaissance Technologies LLC now owns 780,800 shares of the biotechnology company’s stock worth $4,302,000 after buying an additional 335,700 shares during the period. Essex Investment Management Co. LLC grew its position in shares of Adaptimmune Therapeutics PLC by 371.0% in the 2nd quarter. Essex Investment Management Co. LLC now owns 192,045 shares of the biotechnology company’s stock worth $862,000 after buying an additional 151,273 shares during the period. Finally, Wellington Management Group LLP grew its position in shares of Adaptimmune Therapeutics PLC by 17.4% in the 1st quarter. Wellington Management Group LLP now owns 608,633 shares of the biotechnology company’s stock worth $3,354,000 after buying an additional 90,110 shares during the period. 68.01% of the stock is currently owned by hedge funds and other institutional investors.

A number of analysts have recently weighed in on ADAP shares. Zacks Investment Research raised shares of Adaptimmune Therapeutics PLC from a “hold” rating to a “buy” rating and set a $9.75 target price on the stock in a research report on Wednesday. BidaskClub raised shares of Adaptimmune Therapeutics PLC from a “sell” rating to a “hold” rating in a research report on Sunday, July 16th. Leerink Swann reissued an “outperform” rating and set a $15.00 price objective on shares of Adaptimmune Therapeutics PLC in a research report on Friday, September 8th. Finally, ValuEngine raised shares of Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a research report on Thursday, July 20th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $12.38.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/10/08/d-a-davidson-co-sells-1326-shares-of-adaptimmune-therapeutics-plc-adap.html.

Shares of Adaptimmune Therapeutics PLC (NASDAQ ADAP) opened at 8.16 on Friday. Adaptimmune Therapeutics PLC has a 12 month low of $3.76 and a 12 month high of $9.29.

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last posted its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.24). Adaptimmune Therapeutics PLC had a negative return on equity of 38.73% and a negative net margin of 438.00%. The company had revenue of $3.52 million for the quarter, compared to analyst estimates of $5.43 million. On average, analysts expect that Adaptimmune Therapeutics PLC will post ($0.99) earnings per share for the current year.

Adaptimmune Therapeutics PLC Profile

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.

Want to see what other hedge funds are holding ADAP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Adaptimmune Therapeutics PLC (NASDAQ:ADAP).

Institutional Ownership by Quarter for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)

Receive News & Stock Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related stocks with our FREE daily email newsletter.